Previous studies have demonstrated that CCL20 is markedly upregulated in autoimmune disorders such as inflammatory bowel disease (IBD) and arthritis, and anti-CCL20 antibodies have shown efficacy in ameliorating symptoms in clinical trials [45,47]. The gene discussed is CCL20; the disease is Autoimmunity.